Incyte
Developer of Jakafi, Opzelura, and targeted hematology, oncology, and immune-disease medicines.
Something off on this page? Send us feedback.
Breakdown13F · Form 4
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 202.70M · Float —
Float — provider float is below the insider stake.
The provider's float is smaller than the insider stake it should exclude, so it is not shown.
Institutions13F, as of Jun 30, 2026
878 holders · 232.42M shares · 123 new positions · 488 increased · 274 reduced · 80 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Baker Bros. Advisors LP | 30.76M | 15.18% | +17.9K | Aug 14, 2026 |
| BlackRock, Inc. | 18.03M | 8.90% | −945.5K | Aug 7, 2026 |
| Dodge & Cox | 11.96M | 5.90% | −295.0K | Aug 13, 2026 |
| Vanguard Capital Management LLC | 11.02M | 5.44% | +94.2K | Aug 13, 2026 |
| State Street Corp | 9.72M | 4.80% | +81.0K | Aug 7, 2026 |
| Vanguard Portfolio Management LLC | 7.79M | 3.84% | +31.9K | Aug 13, 2026 |
| AQR Capital Management LLC | 5.32M | 2.63% | −487.0K | Aug 14, 2026 |
| Geode Capital Management, LLC | 4.75M | 2.34% | +47.6K | Aug 12, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Felix J. Bakerincl. Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC +4 more | 15.60% | 31.23M | 13D | May 11, 2026 ↗ |
| BlackRock, Inc. | 8.90% | 17.08M | Nov 8, 2024 ↗ | |
| Vanguard Capital Management | 6.32% | 12.59M | 13G | Apr 30, 2026 ↗ |
| Dodge & Cox | 6.20% | 12.25M | 13G | May 14, 2026 ↗ |
| State Street Corporation | 5.50% | 10.55M | Oct 17, 2024 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Baker Bros. Advisors LP | director, 10 percent owner: | 28.21M | 13.92% | Jul 2, 2026 |
| Herve Hoppenot | director | 326.8K | 0.16% | Dec 10, 2025 |
| Pablo J. Cagnoni | officer: President, Global Head of R&D | 183.2K | 0.09% | Aug 20, 2026 |
| William Meury | director, officer: Chief Executive Officer | 183.1K | 0.09% | Jul 20, 2026 |
| Christiana Stamoulis | officer: EVP & Chief Financial Officer | 114.7K | 0.06% | Jul 16, 2025 |
| Paula J. Swain | officer: EVP, Human Resources | 100.1K | 0.05% | Jul 16, 2025 |
| Mohamed Khairie Issa | officer: EVP, Head of U.S. Commercial | 63.9K | 0.03% | Jul 20, 2026 |
| Patrick A. Mayes | officer: EVP & Chief Scientific Officer | 61.4K | 0.03% | Aug 7, 2026 |
| Vijay K. Iyengar | officer: EVP, GMAPPS | 40.5K | 0.02% | Jul 17, 2025 |
| Lee Heeson | officer: EVP, Head of Incyte Intl | 38.0K | 0.02% | Feb 4, 2026 |
5 ten-percent owners hold 6.16M shares by Form 4, outside the officers-and-directors figure above · 30 people have not refiled in the last 18 months (66.84M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 19, 2026 | Pablo J. Cagnoniofficer: President, Global Head of R&D | Sale | 10,801 | $125.56 | 183,200 |
| Aug 12, 2026 | Pablo J. Cagnoniofficer: President, Global Head of R&D | Sale | 10,803 | $120.04 | 194,001 |
| Aug 5, 2026 | Patrick A. Mayesofficer: EVP & Chief Scientific Officer | Sale | 2,207 | $123.99 | 61,441 |
| Aug 5, 2026 | Pablo J. Cagnoniofficer: President, Global Head of R&D | Sale | 10,640 | $122.69 | 204,804 |
| Jul 31, 2026 | Patrick A. Mayesofficer: EVP & Chief Scientific Officer | Sale · 11 lots | 41,899 | $119.46 | 61,441 |
| Aug 3, 2026 | Patrick A. Mayesofficer: EVP & Chief Scientific Officer | Sale | 6,055 | $120.43 | 61,441 |
| Jul 31, 2026 | Pablo J. Cagnoniofficer: President, Global Head of R&D | Sale | 15,888 | $119.70 | 215,444 |
| Jul 16, 2026 | Mohamed Khairie Issaofficer: EVP, Head of U.S. Commercial | Sale | 1,093 | $115.01 | 63,940 |
| Jul 16, 2026 | Steven H. Steinofficer: CMO & Head of Late-Stage Dev. | Sale | 1,877 | $114.73 | 21,118 |
| Jul 15, 2026 | Steven H. Steinofficer: CMO & Head of Late-Stage Dev. | Sale | 28,237 | $113.05 | 26,083 |
CongressHouse and Senate disclosures
Not reported.